Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA

Executive Summary

The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows
Advertisement

Related Content

Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts
E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
Rx Industry Must Take Phase IV “Seriously,” Commissioner Tells PhRMA
Advertisement
UsernamePublicRestriction

Register

PS043635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel